Skip to content

Understanding Quality of Life Among Patients With Cancer Receiving Palliative Care

Understanding Quality of Life Among Patients With Cancer Receiving Palliative Care

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05331625
Enrollment
208
Registered
2022-04-15
Start date
2022-11-03
Completion date
2026-12-01
Last updated
2026-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Brief summary

This randomized controlled trial will assess the effects on quality of life of two approaches to symptom management among new patients referred to a palliative care oncology clinic.

Interventions

BEHAVIORALOffering Additional Resources to Promote Symptom Management

Participants will be offered additional resources to promote symptom management.

Sponsors

Abramson Cancer Center at Penn Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Be a new patient at an outpatient palliative care clinic * Resident of Pennsylvania * Over 18 years of age

Exclusion criteria

* Prior use of certain symptom focused therapies * Currently pregnant

Design outcomes

Primary

MeasureTime frameDescription
Quality of Life - McGill Quality of Life QuestionnaireBaseline - 16 weeksQuality of life will be measured through the McGill Quality of Life Questionnaire Revised (MQOL-R). The questionnaire is 15 questions assessing overall and specific areas of quality of life.

Secondary

MeasureTime frameDescription
Feasibility of Accessing Additional Resources for Symptom ManagementBaseline - 16 weeksFeasibility will be measured by whether participants accessed the additional resources for symptom management.
Acceptability of Accessing Additional Resources for Symptom ManagementBaseline - 16 weeksAcceptability will be measured by whether participants accessed the additional resources for symptom management.
Symptom SeverityBaseline - 16 weeksSymptom severity will be measured through the Edmonton Symptom Assessment System (ESAS). The survey is 10 questions assessing the severity of pain, nausea, depression, etc. on a 0 to 10 scale-in which a 0 representing best possible state/symptom absence and a 10 representing worst possible state.
Medication UseBaseline - 16 weeksMedication use will be measured through a medication diary created for the study. The medication diary asks participants about recent medications, amounts, and dosages.
Hospital-Free DaysBaseline - 16 weeksHospital-free days will be measured through examination of participant's electronic health record.
MortalityBaseline - 16 weeksMortality will be measured through examination of participant's electronic health record.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 17, 2026